TSC22D3 and lung carcinoma: Recent studies have demonstrated that TSC22D3 can impair immune responses by inhibiting the type I interferon responses in dendritic cells and activation of IFN-γ + T cells, which hinders the anticancer immunosurveillance and immunotherapy of lung cancer [29].